Shares of Quest PharmaTech Inc. (CVE:QPT – Get Free Report) reached a new 52-week low on Monday . The company traded as low as C$0.02 and last traded at C$0.03, with a volume of 192998 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Price Performance
The firm’s fifty day simple moving average is C$0.03 and its 200 day simple moving average is C$0.03. The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The company has a market cap of C$4.23 million, a price-to-earnings ratio of 0.83 and a beta of 0.00.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
- Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
